D. E. Shaw & Co. Inc. Grows Position in Dynavax Technologies Co. (NASDAQ:DVAX)

D. E. Shaw & Co. Inc. lifted its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 34.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,918,340 shares of the biopharmaceutical company’s stock after purchasing an additional 486,981 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Dynavax Technologies were worth $24,497,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Deerfield Management Company L.P. Series C increased its position in Dynavax Technologies by 23,990.1% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company’s stock worth $66,325,000 after buying an additional 5,172,263 shares during the period. Deep Track Capital LP grew its holdings in Dynavax Technologies by 42.0% during the fourth quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company’s stock worth $227,197,000 after acquiring an additional 5,265,000 shares during the period. Cresset Asset Management LLC boosted its position in Dynavax Technologies by 5.1% during the fourth quarter. Cresset Asset Management LLC now owns 175,558 shares of the biopharmaceutical company’s stock worth $2,242,000 after purchasing an additional 8,539 shares in the last quarter. Crestline Management LP lifted its position in shares of Dynavax Technologies by 78.3% in the fourth quarter. Crestline Management LP now owns 452,455 shares of the biopharmaceutical company’s stock valued at $5,778,000 after acquiring an additional 198,685 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in Dynavax Technologies during the fourth quarter worth about $2,485,000. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Stock Down 2.9%

NASDAQ:DVAX opened at $9.41 on Monday. The firm has a market capitalization of $1.13 billion, a price-to-earnings ratio of 52.28 and a beta of 1.26. Dynavax Technologies Co. has a 1-year low of $9.28 and a 1-year high of $14.63. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The business’s fifty day moving average price is $12.24 and its 200 day moving average price is $12.58.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.14). The business had revenue of $68.16 million during the quarter, compared to the consensus estimate of $70.01 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. On average, sell-side analysts forecast that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on DVAX shares. StockNews.com lowered Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, May 6th. JMP Securities lowered their target price on Dynavax Technologies from $33.00 to $31.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 7th. The Goldman Sachs Group lowered their price objective on Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating for the company in a research note on Thursday, April 17th. William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, HC Wainwright restated a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Dynavax Technologies has a consensus rating of “Hold” and a consensus target price of $24.00.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.